Register
Four Months of Rifampicin May Be Best Option for Latent TB |
Journal Updates
eMediNexus Coverage from: 
Four Months of Rifampicin May Be Best Option for Latent TB
eMediNexus,  12 January 2020
remove_red_eye 546 Views
#Business And Medicine #Infectious Diseases #Internal Medicine #Pathology and Lab Medicine

2 Read Comments                

Four months of daily rifampicin is "short, safe, and effective" and is likely the best way to achieve the ambitious goal set forth by the World Health Organization (WHO) to treat 30 million patients for latent tuberculosis infection by 2022, TB experts say in Lancet Infectious Diseases.

Across randomized trials and observational studies, compared with isoniazid, four months of daily rifampicin has "consistently" shown better completion rates, lower toxicity, and similar effectiveness, they point out.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now